Strong validation of evaxion's ai-immunology™ platform in multiple clinical trials

Copenhagen, denmark, october 9, 2024 – evaxion biotech a/s (nasdaq: evax) (“evaxion”), a clinical-stage techbio company specializing in developing ai-immunology™ powered vaccines, has now evidence from three different clinical trials validating the vaccine target predictions of its ai platform.
EVAX Ratings Summary
EVAX Quant Ranking